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We are grateful for the comments of Stagno et al.1 on
potential toxicities of infliximab in patients with hemato-
logic malignancies.  
We agree that the occurrence of secondary malignan-
cies could be a potential concern for infliximab use in
patients with low-risk MDS, although none of the 43
patients included in our study developed a secondary
malignancy.2 Similarly, none of the 37 patients with low-
risk MDS treated with infliximab (5 or 10 mg/kg i.v. every
4 weeks for 4 cycles) by Raza et al. developed a second-
ary hematologic malignancy.3 Development of secondary
malignancies is associated with many conditions charac-
terized by chronic inflammation, auto-immunity and
immune suppression even before the introduction of
potent immunomodulators, such as infliximab.4
We share the concern of Stagno et al. about the high
incidence of grade 3-5 infections in our study (30%).1
Interestingly, grade 3-5 infections tended to be more fre-
quent (41%) in patients randomized in the 3 mg/kg arm
than in those randomized in the 5 mg/kg arm (19%).2
Such a high incidence of infection was not observed in
the Raza et al. study in which only one of 37 patients
(3%) experienced a grade 3 infection.3
While the results of our study suggest that infliximab
alone does not have sufficient activity in unselected
patients with early MDS, we agree with Stagno et al.1 that
a combination of infliximab with other MDS active
agents might offer interesting possibilities. Scott et al.
have observed a high durable response rate in MDS
patients treated with a combination of azacitidine and
TNF-α blockade with etanercept, with a relatively low
toxicity profile.5 Similarly, a recent phase II study has
shown encouraging results with a combination of anti-
thymocyte globulin and etanercept in patients with low
or intermediate 1 risk MDS.6
Finally, we agree with Stagno et al.1 that any further
trial assessing infliximab in MDS patients should assess
potential toxicities associated with this drug, and in par-
ticular, severe infections.
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